Skip to content

N-acetylcysteine Effects on Tetrahydrocannabinol

Effect of N-acetylcysteine on the Acute Cognitive Effects of Delta-9-Tetrahydrocannabinol

Status
Terminated
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02335060
Enrollment
5
Registered
2015-01-09
Start date
2014-05-02
Completion date
2014-09-16
Last updated
2022-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

cannabis, Marijuana, THC, N-acetylcysteine, Psychotic Disorders

Brief summary

The overall purpose of this study is to examine the effect of N-acetylcysteine (NAC) on the acute effects of Delta-9-tetrahydrocannabinol (THC). This will be tested by pretreating healthy individuals with NAC and then assessing their responses to THC.

Interventions

Active Delta-9-THC (0.036mg/Kg) given intravenously.

DRUGN-acetylcysteine

A pill given orally.

DRUGPlacebo

Placebo (about a quarter spoon of alcohol with no THC) given intravenously.

Sponsors

Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Exposed to Cannabis at least once in lifetime

Exclusion criteria

* Cannabis Naive * Individuals with a documented allergy to N-acetylcysteine

Design outcomes

Primary

MeasureTime frameDescription
Positive and Negative Symptom Scale for Schizophrenia (PANSS)-30 minutes from administration of THCPositive, negative, and general symptoms will be assessed using the positive, negative, and general symptom subscales of the PANSS

Secondary

MeasureTime frameDescription
Clinician Administered Dissociative Symptoms Scale (CADSS)-60min, -30min, +15min, +90min, +240min from administration of THCPerceptual alterations will be measured using the CADSS. This is a scale consisting of 19 self-reported items and 8 clinician-rated items. The scale captures alterations in environmental/time/body perception, feelings of unreality, and memory impairment.
Visual Analog Scale (VAS)-60min, -30min, +15min, +90min, +240min from administration of THCFeeling states associated with cannabis intoxication will be measured using a self-reported visual analog scale of feeling states associated with cannabis effects (ex: high, calm, anxious). Subjects will be asked to score the perceived intensity of these feeling states at that moment on a 11mm line. These data will be captured to validate that the experiment is relevant to cannabis effects.
Cognitive Test Battery+20min from administration of THCSeveral computer tasks will be administered in order to evaluate the effects of cannabis on recognition memory, working memory, and attention. The battery consists of four computer tasks that lasts no longer than 20 minutes in total.
Hopkins Verbal Learning Test (HVLT)+20min from administration of THCThe HVLT is a 12 word list that is semantically organized. The task consists of 5 trials and a different version of the HVLT will be administered on each test day.
Psychotomimetic States Inventory (PSI)-60min, -30min, +240min from administration of THCThe PSI is a measure of drug induced psychotomimetic states. This self-reported scale consists of 28 items rated 0 (not at all) to 3 (extremely) and will facilitate the characterization of a wide range of dissociative/hallucinatory phenomena as well as cognitive disorganization associated with the administration of THC.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026